Literature DB >> 21072963

[Update on current care guidelines. The diagnosis and medical treatment of memory disorders].

Jaana Suhonen, Tuula Pirttilä, Timo Erkinjuntti, Hannu Koponen, Markku Makkonen, Marja Puurunen, Minna Raivio, Juha Rinne, Ari Rosenvall, Timo Strandberg, Ritva Vanninen, Risto Vataja.   

Abstract

Any complaints from a patient about their memory should be examined. Diagnosis is based on international criteria. The basic evaluation consists of the medical history, clinical evaluation, cognitive tests and brain imaging, especially using MRI. When a diagnosis of Alzheimer's disease, AD with cerebrovascular disease or with Lewy Body disease, or Dementia associated with Parkinson's disease or LBD is made, evidence based medical therapy is indicated as part of comprehensive care. An acetylcholinesterase inhibitor or memantine can be used. These drugs are ineffective in the case of frontotemporal degenerations. For severe behavioural disorders, other psychoactive medications can be applied.

Entities:  

Mesh:

Year:  2010        PMID: 21072963

Source DB:  PubMed          Journal:  Duodecim        ISSN: 0012-7183


  6 in total

1.  Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer's disease research - the Medication use among persons with Alzheimer's disease (MEDALZ-2005) study.

Authors:  Anna-Maija Tolppanen; Heidi Taipale; Marjaana Koponen; Piia Lavikainen; Antti Tanskanen; Jari Tiihonen; Sirpa Hartikainen
Journal:  Clin Epidemiol       Date:  2013-08-07       Impact factor: 4.790

Review 2.  Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors.

Authors:  Anne Leinonen; Marjaana Koponen; Sirpa Hartikainen
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

3.  Regional changes in psychotropic use among Finnish persons with newly diagnosed Alzheimer's disease in 2005-2011.

Authors:  Anna-Maija Tolppanen; Ari Voutilainen; Heidi Taipale; Antti Tanskanen; Piia Lavikainen; Marjaana Koponen; Jari Tiihonen; Sirpa Hartikainen
Journal:  PLoS One       Date:  2017-03-09       Impact factor: 3.240

4.  Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study.

Authors:  Bushra Imtiaz; Marjo Tuppurainen; Toni Rikkonen; Miia Kivipelto; Hilkka Soininen; Heikki Kröger; Anna-Maija Tolppanen
Journal:  Neurology       Date:  2017-02-15       Impact factor: 9.910

5.  History of medically treated diabetes and risk of Alzheimer disease in a nationwide case-control study.

Authors:  Anna-Maija Tolppanen; Piia Lavikainen; Alina Solomon; Miia Kivipelto; Matti Uusitupa; Hilkka Soininen; Sirpa Hartikainen
Journal:  Diabetes Care       Date:  2013-01-22       Impact factor: 19.112

6.  A novel CT-based automated analysis method provides comparable results with MRI in measuring brain atrophy and white matter lesions.

Authors:  Aku L Kaipainen; Johanna Pitkänen; Fanni Haapalinna; Olli Jääskeläinen; Hanna Jokinen; Susanna Melkas; Timo Erkinjuntti; Ritva Vanninen; Anne M Koivisto; Jyrki Lötjönen; Juha Koikkalainen; Sanna-Kaisa Herukka; Valtteri Julkunen
Journal:  Neuroradiology       Date:  2021-08-14       Impact factor: 2.804

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.